At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 4 enrolled
Drug / intervention
BIA 9-1067drug
Likely dose
BIA 9-1067 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites Following a Single-dose Oral Administration
In Brief
A Phase 1 clinical trial evaluating BIA 9-1067 for Parkinson Disease. Completed, enrolled 4 participants across 1 site.
Detailed Summary
To determine the absorption, metabolism and excretion of BIA 9-1067.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesSwitzerland
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
Primary CompletionJun 2009
Study CompletionSep 2010
First PostedJan 2012
TodayJul 2026
First PostedJan 24, 2012
Enrollment StartMay 1, 2009
Primary CompletionJun 1, 2009
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.4 years ago
Interventions
BIA 9-1067drug
90 µCi (3.33 MBq) \[14C\]-labeled of 100 mg BIA 9-1067 (single-dose).